Women’s Imaging Associates implements ScreenPoint Medical’s Transpara® to bring cutting edge 2D and 3D breast AI to benefit the women of Alabama

Share Article

Women’s Imaging Associates and ScreenPoint Medical have announced today a strategic partnership to drive the earlier detection of breast cancer with AI.

Caroline A. Reich, MD, PhD, President & CEO of Women’s Imaging Associates

it (Transpara) integrates seamlessly with our current IT infrastructure and gives us the option of using the Exam Score to prioritize higher risk patients within our worklist.”

As a leading independent teleradiology provider of breast imaging services, Women’s Imaging Associates reviews over 60,000 mammograms for OB-GYN offices, multi-specialty clinics and rural hospitals across the country every year.

All the radiologists at Women’s Imaging Associates are breast imaging experts who meet MQSA accreditation standards and participate in robust quality control and peer review programs. Their expertise allows them to minimize unnecessary callbacks without sacrificing appropriate cancer detection while ensuring that the best study is performed at the appropriate time and tailored to each patient’s individual needs.

Caroline A. Reich, MD, PhD, President & CEO of Women’s Imaging Associates is always at the forefront of implementing new technologies and sees the potential for introducing breast AI at Women’s Imaging Associates to help improve accuracy and workflow.

Dr. Reich states, “After reviewing the evidence, we made the decision to implement Transpara® as it integrates seamlessly with our current IT infrastructure and gives us the option of using the Exam Score to prioritize higher risk patients within our worklist.”

Expectations are, by using Transpara, that Dr. Reich and the team will be able to help improve accuracy with a second set of eyes and decrease time to diagnostic evaluation for patients needing additional imaging or biopsy. Importantly, the team at Women’s Imaging Associates will also be involved in research projects using Transpara to bring further benefits to their customers.

Nico Karssemeijer, CEO and founder of ScreenPoint Medical, added, “We are very excited about this strategic partnership with Women’s Imaging Associates. This gives us a unique opportunity to work with a respected breast imaging provider in the United States. We share the vision with Women’s Imaging Associates that innovative AI solutions are needed to help radiologists deal with increasing demands on quality and efficiency, while diagnostic imaging procedures are getting more complex. This is especially true as we are facing the challenges associated with COVID-19. We are proud that Transpara AI for early detection of breast cancer was selected by Dr Reich and her team.

Transpara® is an AI solution for breast cancer screening, that uses deep learning algorithms to automatically detect lesions suspicious for breast cancer in 2D and 3D mammograms. The software categorises mammograms on a 10-point scale indicating the risk that cancer is present. This Exam Score can be used to help radiologists prioritise patients for further investigation. Decision support marks for calcifications and soft tissue lesions are provided to support radiologists with image interpretation. Studies have shown that Transpara matches the performance of radiologists, thus acting as a second opinion which increases diagnostic confidence and accuracy. It is FDA cleared for 2D and 3D mammography.

1. “Stand-alone artificial intelligence for breast cancer detection in mammography: Comparison with 101 radiologists”, Rodriguez-Ruiz et al, JNCI: Journal of the National Cancer Institute, djy222, https://doi.org/10.1093/jnci/djy222, 2019
2. “Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System” Rodríguez-Ruiz et al, Radiology 290:2, 305-314, 2019.
3. FDA approval number K193229

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Lee
@screenpointmed
since: 10/2016
Follow >
Visit website